Tests oral arsenic trioxide with low-intensity treatment for TP53-mutated blood cancers
Tests oral arsenic trioxide in adults with TP53-mutated myeloid blood cancers.
Key facts
- Who runs it
- The University of Hong Kong
- Where
- Hong Kong, Hong KongSee the site
- Trial code
- Registry title
- Oral-ATO for TP53-mutated Myeloid Malignancies
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 30 people, planned
- Started
- 7 Feb 2025
- Expected to end
- Feb 2028
- Type of study
- Interventional
- Treatments tested
- Oral arsenic trioxide
- Record updated
- 10 June 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with acute myeloid leukemia, myelodysplastic neoplasm or chronic myelomonocytic leukemia that carries a TP53 mutation. It includes people not yet treated and people whose disease came back or did not respond.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Acute myeloid leukemia (AML), myelodysplastic neoplasm (MDS) or chronic myelomonocytic leukemia (CMML) by WHO 2022 criteria. Cohort A: not yet treated. Cohort B: relapsed or refractory after 1 or more lines of earlier treatment. Daily-life activity level (ECOG) of 0-2.
- Earlier treatment
- Cohort A: no earlier treatment. Cohort B: 1 or more earlier lines of treatment that failed. No investigational drug within 14 days (or at least 7 half-lives of that drug, whichever is longer) before the first dose.
- Biomarker or test result
- A TP53 mutation must be present.
Main reasons for not taking part
- Known HIV infection, or known active hepatitis B or hepatitis C
- Uncontrolled, active infection
- Long QT syndrome, or QTcF of 480 ms or more
- Kidney function (GFR) below 40 mL/min, or ALT or AST 3 or more times the upper limit of normal
- Pregnant or breastfeeding, or planning pregnancy during the study
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Willing and able to provide informed consent
- Age ≥18 years
- Diagnosis of acute myeloid leukemia (AML), myelodysplastic neoplasm (MDS) or chronic myelonocytic leukaemia (CMML) by World Health Organization (WHO) 2022 criteria (1, 3)
- Presence of TP53 mutation
- Previously untreated patients for Cohort A (Treatment-naïve), or Patients failing 1 or more lines of prior treatment for Cohort B (Relapsed and Refractory)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Women of childbearing potential and fertile men must agree to use an approved method of contraception from Screening until 30 days after the last dose of oral arsenic trioxide, ascorbic acid, venetoclax and azacitidine/decitabine/oral-decitabine-cedazuridine
- Willing and able to provide informed consent
- Age ≥18 years
- Diagnosis of acute myeloid leukemia (AML), myelodysplastic neoplasm (MDS) or chronic myelonocytic leukaemia (CMML) by World Health Organization (WHO) 2022 criteria (1, 3)
- Presence of TP53 mutation
- Previously untreated patients for Cohort A (Treatment-naïve), or Patients failing 1 or more lines of prior treatment for Cohort B (Relapsed and Refractory)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Women of childbearing potential and fertile men must agree to use an approved method of contraception from Screening until 30 days after the last dose of oral arsenic trioxide, ascorbic acid, venetoclax and azacitidine/decitabine/oral-decitabine-cedazuridine
Who cannot take part
- Use of an investigational agent within 14 days of study treatment (or at least 7 half-lives of that agent, whichever is longer), prior to the first dose of oral arsenic trioxide
- Major surgery within 4 weeks of starting the study drug, or not recovered from side effects of surgery
- Concurrent second active and non-stable malignancy (patients with a concurrent second active but stable malignancy, i.e., non-melanoma skin cancers, are eligible)
- Known hypersensitivity to arsenic trioxide, ascorbic acid, venetoclax or azacitidine/decitabine/oral-decitabine-cedazuridine or their excipients
- Uncontrolled, active infection
- Any other serious medical conditions that could compromise study participation, in the opinion of the investigator
- Known HIV infection or known, active hepatitis B or hepatitis C infection
- Known history of long QT syndrome (LQTS) or corrected QT interval by Fridericia formula (QTcF) ≥ 480 ms
- Evidence at the time of Screening of significant renal or hepatic insufficiency (unless due to hemolysis) as defined by any of the following local laboratory parameters:; Calculated glomerular filtration rate (GFR; using the Cockcroft-Gault equation or eGFR; using CKD-EPI) < 40 mL/min; Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 3 x the local upper limit of normal
- Pregnant or lactating females, or females planning to become pregnant at any time during the study
- Unwilling or unable to comply with the study protocol
Where in Hong Kong
- Queen Mary Hospital - Hong KongHong Kong, Hong KongContact: Harinder Gill, MDTaking people
About the trial
What the trial wants to find out
This is an open-label, phase 2 study of oral arsenic trioxide (Arsenol ®) in combination with ascorbic acid and investigator choice of low-intensity therapy in patients with previously untreated or relapse/refractory TP53-mutated acute myeloid leukemia (AML), myelodysplastic neoplasm (MDS), chronic myelomonocytic leukemia (CMML).
The group in the trial
- Oral arsenic trixoideTreatment being tested
Patients will be treated in 28-day cycles. Each cycles will comprise: Oral ATO (10mg/day or 0.15mg/kg/day in patients \< 50kg) from Days 1-14 PLUS: * Oral ascorbic acid (1000mg/day) from Days 1-14 * Azacitidine (75mg/m2/day s.c. or i.v.) from days 1-7; OR Decitabine (20mg/m2/day i.v.) from days 1-5; OR Oral-decitabine-cedazuridine (1 tablet/day) from days 1-5. * Venetoclax (100mg-400mg/day) from Days 1-14 (if used)
Treatment: Oral arsenic trioxide
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase 2 Study of Oral Arsenic Trioxide (Arsenol ®)-Based Low-intensity Treatment for Previously Untreated or Relapsed/Refractory TP53-mutated Myeloid Malignancies
- Plain-language title
- Tests oral arsenic trioxide with low-intensity treatment for TP53-mutated blood cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 10 June 2025